Shanghai Ruotuo Biotechnology Co. Ltd. has patented antibody-drug conjugates (ADCs) comprising bispecific antibodies targeting epidermal growth factor receptors (EGFR; ERBB; HER) and receptor tyrosine-protein kinase erbb-3 (ERBB3; HER3) linked to a cytotoxic drug through a linker intended for use in the treatment of cancer.
Changchun Genescience Pharmaceuticals Co. Ltd. has discovered salts of fibroblast growth factor receptor 2 (FGFR2) and/or fibroblast growth factor receptor 3 (FGFR3) inhibitors reported to be useful for diagnosis and treatment of cancer, achondroplasia and osteochondrodysplasia.
Researchers from Medizinische Hochschule Hannover and collaborators thus aimed to elucidate signaling adaptations following MAPK pathway inhibition in BRAFV 600E mutant cholangiocarcinoma (CCA) by generating a BRAF V600E-driven model of CCA.
A team of investigators at Icahn School of Medicine at Mount Sinai and collaborating institutions aimed to isolate the on-target activity of CAR T cells to target tumor cells.
More effective glucocorticoid-sparing therapies are needed for the treatment of giant cell arteritis (GCA). Studies found that complement signaling pathways involving complement factor 5 and its receptor (C5aR1) were overexpressed, and that a C5aR1 antagonist, avacopan, reduced the need for glucocorticoids and improved renal recovery. This led researchers to investigate the association of anti-C5aR1 antibodies with GCA and its outcomes.
Applied Biologics LLC has initiated a preclinical research program focused on osteoarthritis and other degenerative diseases. The program marks an expansion of the company’s research and development efforts beyond chronic wounds.
Glucose-dependent insulinotropic polypeptide receptor (GIPR) signaling regulates key metabolic processes, including postprandial insulin secretion, appetite control, lipid storage and overall energy balance. Researchers from Antag Therapeutics Aps presented preclinical efficacy data on the combination of AT-7687, a GIPR antagonist, and cagrilintide in obese insulin-resistant monkeys.
JW Pharmaceutical Corp. has presented data on DDC-02 across animal models of several rare neurodevelopmental disorders, including Pitt-Hopkins syndrome, fragile X syndrome and Rett syndrome. Across these models, DDC-02 consistently restored deficits in cognitive and behavioral function.
Insulin-like growth factor 2 mRNA binding protein 3 (IGF2BP3) is an oncofetal RNA-binding protein aberrantly overexpressed in multiple cancers, where it promotes tumor growth by stabilizing oncogenic mRNAs. Researchers at the University of California described the efficacy of I3IN-002, a potent IGF2BP3 inhibitor, in leukemia models.
Former principal officers of the American Diabetes Association (ADA) have hit back at the association’s board and CEO after it prohibited the distribution of an editorial published in its flagship journal Diabetes Care at the ADA’s meeting in New Orleans last Friday.
RSS
